Cargando…
Gout Treatment and Clinical Considerations: The Role of Pegloticase, Colchicine, and Febuxostat
Gout treatment has evolved rapidly in recent decades, and various drugs have been designed for acute and chronic management. Three medications used to treat gout include pegloticase, colchicine, and febuxostat. When prescribing these drugs, important factors to consider include pharmacokinetics, pha...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10627564/ https://www.ncbi.nlm.nih.gov/pubmed/37937020 http://dx.doi.org/10.7759/cureus.46649 |
_version_ | 1785131550249058304 |
---|---|
author | Quintana, Michael J Shum, Alika Z Folse, Michael S Ramesh, Prerana C Ahmadzadeh, Shahab Varrassi, Giustino Shekoohi, Sahar Kaye, Alan D |
author_facet | Quintana, Michael J Shum, Alika Z Folse, Michael S Ramesh, Prerana C Ahmadzadeh, Shahab Varrassi, Giustino Shekoohi, Sahar Kaye, Alan D |
author_sort | Quintana, Michael J |
collection | PubMed |
description | Gout treatment has evolved rapidly in recent decades, and various drugs have been designed for acute and chronic management. Three medications used to treat gout include pegloticase, colchicine, and febuxostat. When prescribing these drugs, important factors to consider include pharmacokinetics, pharmacodynamics, population specifics, benefits, and contraindications. Pharmacokinetic considerations of each drug include absorption, distribution, metabolism, and elimination factors. Pharmacodynamics factors are assessed by their potential for toxicity and effects on serum uric acid levels. Additionally, the drug’s targeted population must be considered to avoid unwanted complications in certain pre-existing conditions such as cardiovascular disease or glucose-6-dehydrogenase (G6PD) deficiency. In this paper, we aim to provide insight into the gout medications, pegloticase, colchicine, and febuxostat. This review will include their pharmacokinetics, pharmacodynamics, population specifics, benefits, and contraindications. |
format | Online Article Text |
id | pubmed-10627564 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-106275642023-11-07 Gout Treatment and Clinical Considerations: The Role of Pegloticase, Colchicine, and Febuxostat Quintana, Michael J Shum, Alika Z Folse, Michael S Ramesh, Prerana C Ahmadzadeh, Shahab Varrassi, Giustino Shekoohi, Sahar Kaye, Alan D Cureus Rheumatology Gout treatment has evolved rapidly in recent decades, and various drugs have been designed for acute and chronic management. Three medications used to treat gout include pegloticase, colchicine, and febuxostat. When prescribing these drugs, important factors to consider include pharmacokinetics, pharmacodynamics, population specifics, benefits, and contraindications. Pharmacokinetic considerations of each drug include absorption, distribution, metabolism, and elimination factors. Pharmacodynamics factors are assessed by their potential for toxicity and effects on serum uric acid levels. Additionally, the drug’s targeted population must be considered to avoid unwanted complications in certain pre-existing conditions such as cardiovascular disease or glucose-6-dehydrogenase (G6PD) deficiency. In this paper, we aim to provide insight into the gout medications, pegloticase, colchicine, and febuxostat. This review will include their pharmacokinetics, pharmacodynamics, population specifics, benefits, and contraindications. Cureus 2023-10-07 /pmc/articles/PMC10627564/ /pubmed/37937020 http://dx.doi.org/10.7759/cureus.46649 Text en Copyright © 2023, Quintana et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Rheumatology Quintana, Michael J Shum, Alika Z Folse, Michael S Ramesh, Prerana C Ahmadzadeh, Shahab Varrassi, Giustino Shekoohi, Sahar Kaye, Alan D Gout Treatment and Clinical Considerations: The Role of Pegloticase, Colchicine, and Febuxostat |
title | Gout Treatment and Clinical Considerations: The Role of Pegloticase, Colchicine, and Febuxostat |
title_full | Gout Treatment and Clinical Considerations: The Role of Pegloticase, Colchicine, and Febuxostat |
title_fullStr | Gout Treatment and Clinical Considerations: The Role of Pegloticase, Colchicine, and Febuxostat |
title_full_unstemmed | Gout Treatment and Clinical Considerations: The Role of Pegloticase, Colchicine, and Febuxostat |
title_short | Gout Treatment and Clinical Considerations: The Role of Pegloticase, Colchicine, and Febuxostat |
title_sort | gout treatment and clinical considerations: the role of pegloticase, colchicine, and febuxostat |
topic | Rheumatology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10627564/ https://www.ncbi.nlm.nih.gov/pubmed/37937020 http://dx.doi.org/10.7759/cureus.46649 |
work_keys_str_mv | AT quintanamichaelj gouttreatmentandclinicalconsiderationstheroleofpegloticasecolchicineandfebuxostat AT shumalikaz gouttreatmentandclinicalconsiderationstheroleofpegloticasecolchicineandfebuxostat AT folsemichaels gouttreatmentandclinicalconsiderationstheroleofpegloticasecolchicineandfebuxostat AT rameshpreranac gouttreatmentandclinicalconsiderationstheroleofpegloticasecolchicineandfebuxostat AT ahmadzadehshahab gouttreatmentandclinicalconsiderationstheroleofpegloticasecolchicineandfebuxostat AT varrassigiustino gouttreatmentandclinicalconsiderationstheroleofpegloticasecolchicineandfebuxostat AT shekoohisahar gouttreatmentandclinicalconsiderationstheroleofpegloticasecolchicineandfebuxostat AT kayealand gouttreatmentandclinicalconsiderationstheroleofpegloticasecolchicineandfebuxostat |